Members of the mitogen-activated protein kinase (MAPK) family, including
Friend spleen focus-forming virus (SFFV), in conjunction with its natural helper virus Friend murine leukemia virus (MuLV), causes a rapid erythroleukemia when injected into susceptible adult or newborn mice (for a review, see reference 48) . Friend SFFV, a replication-defective retrovirus, carries a unique env gene encoding a 55-kDa glycoprotein, which is responsible for its pathogenicity. The first stage of Friend SFFV-induced disease is characterized by splenomegaly and polycythemia, which is due to the polyclonal expansion and differentiation of erythroid cells in the absence of the erythroid hormone erythropoietin (Epo). This Epo-independent erythroblastosis is due to the interaction at the cell surface of SFFV gp55 with the erythropoietin receptor (EpoR) and a short form of the receptor tyrosine kinase Stk (sf-Stk) (6, 13, 25, 39) . This interaction results in the constitutive activation of Epo and/or Stk signal transduction pathways, including the Ras/Raf-1/mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase, and Jak/STAT pathways (32, 33, 38, 40) . The second stage of the disease consists of the outgrowth of Friend SFFVinfected erythroid cells that have become transformed due to integration of the virus into the Sfpi-1 locus (31, 43, 44) . This leads to inappropriate expression of the Sfpi-1 gene product, PU.1, in erythroid cells, causing a block in their differentiation and the outgrowth of transformed erythroleukemia cells (50) .
Friend MuLV, the natural helper virus for Friend SFFV, can also cause erythroleukemia, characterized by splenomegaly and severe anemia, if injected alone into newborn mice (55) . Unlike Friend SFFV, Friend MuLV is replication competent and does not carry any unique genes that are required for its pathogenicity. Rather, Friend MuLV interacts with specific endogenous retroviral envelope gene sequences in the mouse, generating a new virus, Friend mink cell focus-inducing virus, which is responsible for the first stage of the disease (47) . The erythroid hyperplasia induced by Friend MuLV, in contrast to that induced by Friend SFFV, still requires Epo. Friend MuLV-induced erythroleukemia also has a transformation stage, which can be detected after several passages of primary erythroleukemic cells in mice. These cells have become transformed primarily due to virus integration at the Fli-1 locus, resulting in up-regulation of the Fli-1 protein in erythroid cells (2, 3) . Both PU.1 and Fli-1 belong to the ets oncogene family and have the ability to bind to specific DNA sequences. This allows them to alter the expression of distinct downstream target genes, consistent with their nonoverlapping involvement in the induction of erythroleukemias by Friend SFFV or Friend MuLV. Overexpression of PU.1 and Fli-1 blocks the differentiation of erythroid cells (50, 54) , perhaps through modulating the Epo/EpoR or sf-Stk signal transduction pathways.
The MAP kinases constitute an important group of serine/ threonine signaling kinases that modulate the phosphorylation, and therefore the activation status, of transcription factors and link transmembrane signaling with gene induction events in the nucleus (37) . It has been shown that Epo can activate components of the MAP kinase pathway, including extracellular signal-related kinase (ERK), p38 MAPK, and Jun N-terminal kinase (JNK) (20, 30, 34, 35) . Withdrawal of Epo has also been shown to activate p38 MAPK (56) . JNKs were first described biochemically following exposure of cells to environmental stresses (23, 24) and are now recognized as being activated in a variety of cells by cytokines and growth factors (17) . The JNKs have also been characterized by their ability to associate with and phosphorylate regulatory sites in the N terminus of the transcription factor c-Jun, a member of the activator protein 1 (AP1) complex (9) and to phosphorylate transcription factors such as ATF-2, ELK-1, NFAT, and p53 (8, 14, 28, 63) . Although it has been shown that Friend SFFV, like Epo, can activate the MAP kinase ERK (32), little is known about the ability of Friend SFFV or Friend MuLV to activate JNK or the role of any of the MAP kinases in the proliferation and survival of Friend SFFV and Friend MuLV-induced erythroleukemia cells. The purpose of this study, therefore, was to investigate the role of MEK/ERK and JNK, using specific pharmacological inhibitors for these kinases, in the proliferation and survival of murine erythroleukemia cells.
Cell cycle and flow cytometry. The cell cycle was analyzed by using flow cytometry of propidium iodide (PI)-stained cells. Cells (1 ϫ 10 6 ) were fixed in 70% ethanol overnight at 4°C. The cells were washed in phosphate-buffered saline with 0.1% BSA. Cells were incubated with 1 U/ml of RNase A (DNase free) and 10 g/ml of PI (Sigma Chemical Corp., St. Louis, MO) overnight at room temperature in the dark. Cells were analyzed by using a FACScan flow cytometer (Becton Dickenson, Rutherford, N.J.). Amounts of cells containing sub-G 1 DNA, indicating apoptosis, were determined as a percentage of the total number of cells. For annexin V staining, live cells were washed in phosphatebuffered saline and then incubated with annexin V-fluorescein isothiocyanate (R&D Systems, Minneapolis, MN) and PI for 15 minutes. Cells were analyzed using the FACScan flow cytometer.
Protein analysis. Cell lysates were prepared by resuspending cells in lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 , 1 g/ml each of aprotinin and leupeptin), followed by incubation on ice for 20 min. Insoluble components were removed by centrifugation, and protein concentrations were determined with a protein assay kit (Bio-Rad Laboratories, Hercules, Calif.). Proteins were separated by electrophoresis on Tris-glycine or NuPAGE Bis-Tris minigels (Invitrogen, Carlsbad, CA) and then transferred electrophoretically to nitrocellulose filters for Western blotting with anti-JNK, antiphospho JNK, anti-MEK, and anti-phospho-MEK antibodies (Cell Signaling Technology, Beverly, MA, or Upstate Biotechnology, Lake Placid, NY), followed by visualization using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, N.J.).
Electrophoretic mobility shift assays. Nuclear extracts were prepared as previously described (40) and used in electrophoretic mobility shift assays. Ten to 30 g of nuclear extract was incubated with a [
32 P]ATP-labeled double-stranded DNA fragment corresponding to the consensus binding site for AP1 (sense strand, 5ЈCGCTTGATGACTCAGCCGGAA3Ј) or an AP1 mutant oligonucleotide (sense strand, 5ЈCGCTTGATGACTTGGCCGGAA3Ј) at room temperature for 30 min in the presence of binding buffer (13 mM HEPES [pH 7.9], 80 to 120 mM NaCl, 0.15 mM EDTA, 8% glycerol, and 1 mM dithiothreitol), 1 g BSA, 0.25ϫ protease inhibitor cocktail, 0.05% NP-40, and 3 g of poly(dI-dC). A mutant AP1 oligonucleotide with a substitution of TG for CA in the AP1 binding motif was used as a negative control. Samples were then subjected to electrophoresis using a 6% polyacrylamide gel containing 5% glycerol with 0.5ϫ Tris-borate-EDTA buffer. Gels were dried and complexes visualized by autoradiography. The integrity of the nuclear extracts obtained from drug-treated cells was demonstrated using a specific probe for another transcription factor (STAT5).
Statistical analysis. Statistical methods used in this study included Leven's test, one-way analysis of variance, Welch's modified one-way analysis of variance, and the Dunnett test for post hoc comparisons.
RESULTS
MEK and JNK are constitutively phosphorylated in primary leukemic spleens and erythroleukemia cell lines derived from Friend SFFV-infected mice. We previously demonstrated that Epo activates the Ras-Raf-MEK-ERK pathway in the Epo-dependent erythroleukemia cell line HCD-57 and that infection of these cells with Friend SFFV results in constitutive activation of this pathway (32) . To determine if Friend SFFV infection of erythroid cells also results in the constitutive activation of JNK, we examined cells grown in the absence of Epo for the expression of phosphorylated JNK. As shown in Fig.  1A , JNK is phosphorylated in uninfected HCD-57 cells after stimulation with Epo but is constitutively phosphorylated in Friend SFFV-infected HCD-57 cells. JNK is also highly phosphorylated in primary leukemic spleens from Friend SFFVinfected mice (Fig. 1B) , in five independently derived erythroleukemia cell lines from mice infected with helper-free Friend SFFV (Fig. 1C ) and in five independent erythroleukemia cell lines from Friend MuLV-infected mice (Fig. 1D) . Differences in the amounts of pJNK1 and pJNK2 were observed between the SFFV MEL lines and the F-MuLV MEL lines and may be due to differences in the stages of erythroid cell differentiation VOL. 79, 2005 ACTIVATION OF THE JNK PATHWAY BY FRIEND SFFV 12753 between the cell lines. MEK is phosphorylated in all of these erythroleukemia cells (Fig. 1A to D) . Both MEK and JNK inhibitors block the proliferation of uninfected and Friend SFFV-infected HCD-57 cells. Previous studies have shown that the Epo-dependent proliferation of erythroid cells is dependent upon MEK/ERK and JNK (18, 27, 33) . To determine whether Friend SFFV infection of erythroid cells alters their requirement for these kinases, we compared the Epo-dependent cell line HCD-57 with its Friend SFFVinfected, Epo-independent counterpart for their sensitivity to the MEK inhibitor PD98059 as well as to the JNK inhibitor SP600125, which blocks both JNK1 and JNK2. After treatment of these cells with PD98059 or SP600125 for 48 h, the amount of ERK or JNK kinase activity, respectively, was negligible (data not shown). To determine the effect of each inhibitor on the proliferation of these cells, the cells were grown in the presence of various concentrations of the inhibitor for 48 h and cell proliferation was determined using the WST-1 reagent. As shown in Fig . Western blot analysis of total cell lysates was carried out using anti-phospho-JNK and anti-phospho-MEK antibodies. The filters were stripped and then incubated with anti-JNK or anti-MEK antibodies to determine total kinase levels.
Friend SFFV-induced erythroleukemia occurs in two stages (for a review, see reference 48). In the first stage, Friend SFFV causes Epo-independent erythroid proliferation and differentiation in the animal. Primary erythroleukemic splenocytes from these animals can grow in liquid culture for only a short time but can both proliferate and differentiate in semisolid medium, forming hemoglobin-positive erythroid colonies. In the second stage, Friend SFFV-infected erythroid cells become blocked in differentiation, resulting in the outgrowth of transformed erythroleukemia cells that can be grown as cell lines. As shown in Fig. 1B and C, cells from both stages show constitutive activation of MEK and JNK. To determine what role these constitutively activated kinases play in cells derived from both stages of SFFV disease, we used the inhibitors PD98059 and SP600125 to inhibit MEK and JNK, respectively.
As shown in Fig. 3 , both PD98059 (panel A) and SP600125 (panel B) inhibited the liquid growth of primary erythroleukemic splenocytes from Friend SFFV-infected mice in a dosedependent fashion, with kinetics similar to that seen using Friend SFFV-infected HCD-57 cells. In contrast to HCD-57 cells (Fig. 2C) , neither the MEK nor the JNK inhibitor caused an increase in the percentage of primary erythroleukemia cells undergoing apoptosis (data not shown), and no multinucleated cells were observed. Since a previous study showed that antisense JNK oligonucleotides induced apoptosis only in p53-deficient human tumor lines (45) , it is possible that the failure of primary erythroleukemia cells from SFFV-infected mice to undergo apoptosis in response to JNK inhibition may reflect their wild-type-p53 status.
When primary erythroleukemia cells were plated in the SFFV CFU assay with or without inhibitors, the formation of large, hemoglobin-positive colonies, which represent primarily proliferating cells, was significantly reduced in the presence of both the MEK inhibitor PD98059 (P was 0.004 at 50 M and Ͻ0.001 at 100 M) and the JNK inhibitor SP600125 (P was 0.001 at 10 M) (Fig. 3C) . In contrast, the formation of small hemoglobin-positive colonies, which represent differentiating cells, was not significantly reduced after treatment with either inhibitor (P Ͼ 0.1). This suggests that MEK and JNK inhibitors may predominantly block a proliferation pathway in Friend SFFV-infected erythroid cells rather than a differentiation pathway.
We next examined five independently derived immortal erythroleukemia cell lines from Friend SFFV-infected mice. As shown in Fig. 4 , the MEK inhibitor PD98059 had little effect on the growth of any of these cells, even after 48 h (panel A). In contrast, the JNK inhibitor SP600125 dramatically inhibited the growth of all of these cell lines as early as 24 h (Fig. 6B) , we could detect a modest increase in the percentage of apoptotic cells in four out of five of the cultures treated with the MEK inhibitor (15 to 27%; P was 0.005 to Ͻ0.001). In contrast to the Friend SFFV-induced erythroleukemia cell lines, the Friend MuLV-induced cell lines were less susceptible to apoptosis induced by the JNK inhibitor, with all lines showing a modest increase in the percentage of apoptotic cells (P was 0.015 to Ͻ0.001) but only two of five lines showing greater than 30% apoptosis after drug treatment for 48 h. Differences in sensitivity to apoptosis after JNK inhibition are not due to the p53 status of the cells because all of the F-MuLV MEL lines were mutant or null for p53 (data not shown).
Cell cycle analysis in erythroleukemia cell lines treated with the JNK inhibitor. In all of the erythroleukemia cell cultures grown in the presence of the JNK inhibitor SP600125 for 3 to 5 days, we saw evidence of multinucleated (polyploid) cells. This prompted us to test the effect of SP600125 treatment on the cell cycle. All of the Friend SFFV-transformed erythroleukemia cell lines, including NP4 and NP7 (Fig. 7A) and NP1, NP5, and NP13 (data not shown) showed similar patterns of the cell cycle after treatment with SP600125. After 12 h of exposure to the drug, 62% of NP4 cells and 84% of NP7 cells stained for DNA content in a manner consistent with the G 2 /M phase of the cell cycle, in comparison with 23% and 16%, respectively, after treatment with DMSO. At 24 h after drug treatment, the cells entered the endoreduplication cycle, with 32% of NP4 and 19% of NP7 cells showing a DNA content of 8N (polyploid). Twenty-four hours after drug treatment, 56% of NP4 and 29% of NP7 cells stained for DNA in a manner consistent with the G 0 /G 1 phase, which includes apoptotic cells. The Friend MuLV-induced erythroleukemia cell lines TP3 and CB7 also showed a large increase in the percentage of cells in the G 2 /M phase after treatment with SP600125 for 12 h, with 76% of TP3 cells and 58% of CB7 cells staining for G 2 /M DNA (Fig. 7B ) in comparison with DMSO-treated cells (21% for TP3 and 22% for CB7). Similar results were obtained with TP1 and HB22.2 (data not shown). Differences were noted, however, after 24 h of treatment with SP600125, and the results directly correlated with the sensitivity of the cells to the induction of apoptosis by the JNK inhibitor. Fifteen percent of TP3 cells (Fig. 7B) and 35% of TP1 cells (data not shown), both of which are sensitive to apoptosis induction by SP600125 (Fig.  6B) , showed a DNA content of 8N (polyploid) 24 h after SP600125 treatment, and 43% of TP-3 ( Fig. 7B) and 35% of TP1 (data not shown) cells were in the sub-G 1 phase. In contrast, CB7 cells (Fig. 7B ) and HB22.2 cells (data not shown), neither of which are very sensitive to apoptosis induction by SP600125, continued to accumulate in the G 2 /M phase and showed no evidence of apoptosis. As noted above, these differences were not related to the p53 status of the cell lines. Treatment of any of the erythroleukemia cell lines with the MEK inhibitor PD98059 did not induce an accumulation of cells in the G 2 /M phase or polyploidy (data not shown). These results suggest that in the majority of erythroleukemia cell lines, whether they are induced with Friend SFFV or Friend MuLV, the JNK inhibitor SP600125 induces an accumulation of cells in the G 2 /M phase of the cell cycle, with some of the erythroleukemia cells going into apoptosis and others into an endoreduplication cycle.
Regulation of AP1 activity through JNK in erythroleukemia cells. AP1 is one of the downstream molecules that is regulated by JNK and MEK (21) . We, therefore, investigated whether mouse erythroleukemia cells express AP1 DNA-binding activity and whether or not it is regulated by JNK. It has previously been demonstrated that Epo induces AP1 DNA binding in Epo-dependent cells (5, 19, 42) . Using AP1 consensus and mutant probes in electrophoretic mobility shift assays, we could detect constitutive AP1 DNA-binding activity in all of the virus-infected erythroleukemia cells examined, including primary splenocytes from Friend SFFV-infected mice (Fig. 8,  lanes 2 ). In contrast, erythroblasts from the spleens of uninfected mice or primary leukemic splenocytes from mice infected with Friend MuLV showed AP1 DNA-binding activity only in the presence of Epo (data not shown). In HCD-57 cells and Friend SFFV-infected HCD-57 cells examined 24 h after treatment with SP600125, AP1 DNA-binding activity decreased compared to that in control cells (Fig. 8A, lanes 4) . Treatment of primary erythroleukemic splenocytes from points in the first 24 h of treatment with SP600125, even though SP600125 inhibited cell growth and induced apoptosis (data not shown). In contrast, PD98059 treatment of all erythroleukemia cells examined resulted in a decrease in AP1 DNAbinding activity (Fig. 8A to D, lanes 3) , even though proliferation of Friend SFFV-transformed erythroleukemia cells was not inhibited by the MEK inhibitor (Fig. 4A) . These results suggest that in all of the Friend MuLV-transformed erythroleukemia cell lines examined and in primary erythroleukemia cells, AP1 DNA-binding activity is regulated, at least in part, by both the MEK and JNK pathways, whereas in Friend SFFV-transformed erythroid cells, the MEK pathway, but not the JNK pathway, has a role in AP1 DNA binding.
DISCUSSION
In Epo-dependent erythroid cells, the MAP kinases ERK and JNK have been shown to promote proliferation (20) . Infection of Epo-dependent erythroid cells with Friend SFFV renders them Epo independent, and this is associated with the constitutive activation of various Epo signal transduction pathways, including the ERK pathway (32) . In this study, we show that the JNK pathway is also constitutively activated in erythroid cells infected with Friend SFFV. To determine whether constitutive activation of the ERK and/or JNK pathways promotes the proliferation of Friend SFFV-infected erythroid cells, we took advantage of specific pharmacological inhibitors of these pathways. PD98059, a potent inhibitor of MEK, which activates ERK 1 and ERK 2, blocked the growth of Friend SFFV-infected HCD-57 cells and primary erythroleukemic spleens from Friend SFFV-infected mice but surprisingly had no effect on the growth of immortal erythroleukemia cell lines derived from these mice. PD98059, however, was a potent inhibitor of immortal erythroleukemia cell lines derived from mice infected with Friend MuLV. In contrast to the MEK inhibitor, SP600125, a specific inhibitor of JNK1 and JNK2, was a potent inhibitor of the growth of all erythroleukemia cell lines examined. The SP600125-treated erythroleukemia cell lines all showed significant apoptosis as determined either by analyzing the number of cells in the sub-G 1 fraction or by annexin V staining. Interestingly, when we compared HCD-57 cells and Friend SFFV-infected HCD-57 cells after treatment with SP600125, we found similar kinetics of cell growth inhibition but observed that Friend SFFV-infected HCD-57 cells were more sensitive to the induction of apoptosis after drug treatment than uninfected HCD-57 cells, suggesting that JNK may play an important role for antiapoptosis in Friend SFFVinfected erythroid cell lines. In contrast to what occurred with erythroleukemia cell lines, inhibition of JNK did not induce apoptosis in primary erythroleukemia cells from Friend SFFVinfected mice. This may reflect the wild-type-p53 status of these primary cells or may suggest that JNK does not play an antiapoptotic role in primary erythroleukemic spleens from Friend SFFV-infected mice. We conclude from our data that Although our data indicate that the JNK pathway is important for the growth and survival of Epo-independent erythroleukemia cells, the role that the pathway plays in these cells is unclear. Mice with homozygous deletions of either JNK1 (10) or JNK2 (62) fail to show any abnormalities in erythropoiesis, and deletion of both JNK1 and JNK2 (22) , while lethal to the embryo, does not affect the development of the fetal liver, the site of erythropoiesis in the fetus. JNKs do play a role in tetradecanoylphorbol-13-acetate-induced papilloma progression, where JNK1 acts as a suppressor of skin tumor development (51) and JNK2 is critical in the tumor promotion process (7). It will be interesting to test if the progressions of erythroleukemia induced by Friend SFFV and Friend MuLV are different in JNK1-and JNK2-deficient mice. In all of the erythroleukemia cell lines treated with SP600125, we observed an accumulation of cells in the G 2 /M phase of the cell cycle, consequent apoptosis, and endomitosis. Previous studies have suggested a role for JNK in the cell cycle (61) . Active JNK is at the centrosome from S phase to anaphase (26) . Also, the JNK inhibitor SP600125 has been reported to cause G 2 /M arrest or endoreduplication in a variety of human cancer cell lines, including multiple myeloma, breast cancer, prostate cancer, and erythroleukemia (11, 15, 18, 29, 58) . In Friend virus-induced SKT6 cells, which unlike the cells used in this study can differentiate in response to Epo, antisense oligonucleotides of JNK1 and JNK2 inhibited Epo-induced differentiation (36) , although cell cycle analysis was not shown. In another study, expression of a dominant negative form of JNK1 inhibited the Epo-dependent proliferation of HCD-57 erythroleukemia cells but did not increase the fraction of cells in G 2 /M or the number undergoing endoreduplication (18) . In our studies, treatment of erythroleukemia cell lines with the JNK inhibitor SP600125 did not induce their differentiation (data not shown).
Because the JNK pathway can regulate AP1 activity, we investigated AP1 DNA binding in the erythroleukemia cells used in this study. Although it has previously been shown that Epo induces AP1 DNA-binding activity in Epo-dependent cells (5, 19, 42) , our data are the first to demonstrate that AP1 DNA binding is constitutive in Friend SFFV-infected HCD-57 cells, in primary splenocytes from Friend SFFV-infected mice, and in erythroleukemia cell lines from Friend SFFV and Friend MuLV-infected mice. By examining AP1 DNA binding in these cells before and after treatment with the JNK inhibitor, we were able to evaluate whether the JNK inhibitor may block the proliferation of these cells by inhibiting AP1 activity. Our data showed that AP1 activity in Friend SFFV-infected HCD-57 cells, in primary splenocytes from Friend SFFV-infected mice, and in erythroleukemia cell lines from Friend MuLV-infected mice was reduced after treatment of the cells with the JNK inhibitor SP600125. However, treatment with SP600125 had no effect on AP1 DNA binding in erythroleukemia cell lines from mice infected with Friend SFFV, even though the drug inhibits cell proliferation. Thus, AP1 DNA binding appears to be regulated by the JNK pathway and correlates with cell proliferation in some erythroleukemia cells but not others. Although loss of AP1 DNA binding after treatment of F-MuLV MEL lines with the JNK inhibitor correlates with inhibition of cell proliferation, it will be necessary to specifically block AP1 DNA-binding activity in these cells in order to determine if AP1 is essential for their growth. A previous study showed that the components in the AP1 complex activated after Epo stimulation of HCD-57 cells differed from the components in the AP1 complex activated after Epo withdrawal from HCD-57 cells (19) . Also, it was recently shown that fibroblasts from mice deficient for JNK1 and JNK2 showed decreased expression of some but not all AP1 components (57) . Perhaps the components in the AP1 complex activated in the Friend SFFV-induced erythroleukemia cell lines are different from those in the other erythroleukemia cells examined in this study and that only the components in the latter cells are under JNK regulation. Interestingly, the MEK inhibitor was able to reduce AP1 DNA binding in the Friend SFFV-induced erythroleukemia cell lines, even though it did not alter the growth of these cells. This suggests that the components of the AP1 complex activated in the Friend SFFVinduced erythroleukemia cell lines may be regulated by the MEK pathway but not by JNK. We could not detect any differences, either before or after drug treatment, in the expression of AP1 components (c-Jun, JunB, JunD, and c-Fos) in MEL cells from Friend SFFV-versus F-MuLV-infected mice (data not shown). Since JNK also regulates other transcription factors in addition to AP1, it will be interesting to determine if the activity of any of these is altered after treatment of the various erythroleukemia cell lines with the JNK inhibitor.
In conclusion, our study highlights the importance of the JNK pathway in maintaining the growth and survival of a diverse group of mouse erythroleukemia cells. In light of our data, inhibition of JNK using the drug SP600125 might be a useful strategy for treating erythroleukemia in humans.
